0000000000365357

AUTHOR

Tiziana Latiano

showing 4 related works from this author

Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study.

2012

ABSTRACT Background Data are limited regarding bone metastases from colorectal cancer (CRC). The objective of this study was to survey the natural history of bone metastasis in CRC. Patients and methods This retrospective, multicenter, observational study of 264 patients with CRC involving bone examined cancer treatments, bone metastases characteristics, skeletal-related event (SRE) type and frequency, zoledronic acid therapy, and disease outcomes. Results Most patients with bone metastases had pathologic T3/4 disease at CRC diagnosis. The spine was the most common site involved (65%), followed by hip/pelvis (34%), long bones (26%), and other sites (17%). Median time from CRC diagnosis to b…

Oncologymedicine.medical_specialtyBone Density Conservation AgentSettore MED/06 - Oncologia MedicaColorectal cancerBone NeoplasmsColorectal NeoplasmBone Neoplasmdrug therapy/pathologyZoledronic AcidInternal medicinemedicineHumansImidazolePelvisRetrospective Studiesdrug therapy/secondarybone metastases colorectal cancer zoledronic acidBone Density Conservation AgentsDiphosphonatesbusiness.industryImidazolesBone metastasisCancerRetrospective cohort studyHematologymedicine.diseaseNatural historyBone Density Conservation AgentsZoledronic acidmedicine.anatomical_structureDiphosphonateOncologytherapeutic useBone Density Conservation Agents; therapeutic use; Bone Neoplasms; drug therapy/secondary; Colorectal Neoplasms; drug therapy/pathology; Diphosphonates; Humans; Imidazoles; Retrospective StudiesbusinessColorectal NeoplasmsHumanmedicine.drug
researchProduct

Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial

2015

Background: Evidence suggests that metastatic colorectal carcinoma (mCRC) has a high level of intratumor heterogeneity. We carried out a quantitative assessment of tumor heterogeneity for KRAS, NRAS, BRAF and PIK3CA mutations, in order to assess potential clinical implications. Patients and methods: Tumor samples (n = 182) from the CAPRI-GOIM trial of first-line cetuximab + FOLFIRI in KRAS exon-2 wild-type mCRC patients were assessed by next-generation sequencing that allows quantitative assessment of mutant genes. Mutant allelic frequency was normalized for the neoplastic cell content and, assuming that somatic mutations usually affect one allele, the Heterogeneity Score (HS) was calculate…

OncologyNeuroblastoma RAS viral oncogene homologOrganoplatinum CompoundsColorectal cancerSettore MED/06 - Oncologia MedicaLeucovorinCetuximabCetuximab; Colorectal cancer; Mutations; Next-generation sequencing; Tumor heterogeneity; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Drug Resistance Neoplasm; Fluorouracil; GTP Phosphohydrolases; Gene Frequency; High-Throughput Nucleotide Sequencing; Humans; Leucovorin; Membrane Proteins; Mutation; Organoplatinum Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Treatment Outcome; Hematology; OncologyColorectal Neoplasmmedicine.disease_causeGTP PhosphohydrolasesGTP PhosphohydrolasePhosphatidylinositol 3-KinasesGene FrequencyAntineoplastic Combined Chemotherapy ProtocolsMembrane ProteinClass I Phosphatidylinositol 3-KinasecolorectalCetuximabHigh-Throughput Nucleotide SequencingHematologyTreatment OutcomeOncologyFOLFIRIKRASFluorouracilColorectal Neoplasmsmedicine.drugHumanProto-Oncogene Proteins B-rafmedicine.medical_specialtyTumor heterogeneityClass I Phosphatidylinositol 3-KinasesProto-Oncogene Proteins p21(ras)Internal medicinemedicinecancerHumansneoplasmsAllele frequencyAntineoplastic Combined Chemotherapy ProtocolSettore MED/08 - ANATOMIA PATOLOGICAbusiness.industryCarcinomaOrganoplatinum CompoundMembrane ProteinsCancermedicine.diseaseColorectal cancerdigestive system diseasesDrug Resistance NeoplasmMutationCancer researchNext-generation sequencingNeoplastic cellCamptothecinPhosphatidylinositol 3-Kinasebusiness
researchProduct

Tuning gut microbiota through a probiotic blend in gemcitabine‐treated pancreatic cancer xenografted mice

2021

Medicine (General)Transplantation HeterologousMedicine (miscellaneous)Gut floraSettore MED/08 - Anatomia PatologicaDeoxycytidineLetter to Editorlaw.inventionProbioticMiceR5-920lawPancreatic cancermedicineAnimalsbiologybusiness.industryProbioticsbiology.organism_classificationmedicine.diseaseGemcitabineGemcitabineGastrointestinal Microbiomegut microbiota gemcitabine pancreatic cancer xenografted micePancreatic NeoplasmsCancer researchMolecular Medicinebusinessmedicine.drugClinical and Translational Medicine
researchProduct

Association Between Previously Identified Disease Loci At Chr12q15 and Chr1p36 and UC in Italian Population

2009

IBDDisease loci
researchProduct